Search the Newsreel

Bicycle Therapeutics plc Stock 12‑Month Price Target Cut to $10.29, Implies 166% Upside

Bicycle Therapeutics plc (BCYC) has seen its average 12-month price target cut to $10.29 from $10.43 by 7 analysts, implying a potential upside of 166% from its July 29 closing price. Despite the target reduction, the consensus rating from 9 covering analysts remains "Buy," …

PURECYCLE TECHNOLOGIES INC UNIT 1 COM & 3/4 WT EXP(17/06/2026)(PCTTU.US) will release its earnings report after market close on August 6.

PureCycle Technologies Inc. (PCTTU.US) is scheduled to release its earnings report after the market closes on August 6th. Investors and analysts will be anticipating these results to assess the company's financial performance.

RBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)

Bicycle Therapeutics Stock Price Forecast. Should You Buy BCYC?

Pure Cycle Corp (PCYO) Financial Health: Profitability & Balance Sheet Analysis

Pure Cycle Corp (PCYO) currently holds a stable financial score of 7.37, ranking 7th out of 14 in the Water & Related Utilities industry. The company reported a significant year-over-year revenue increase of 59.96% to $8.22M and a net profit increase of 30.67%. Despite …

UNCY|Unicycive Therapeutics Inc|Price:5.285|Chg%:+0.545

This article provides a comprehensive stock analysis of Unicycive Therapeutics Inc (UNCY) by TradingKey, detailing its stock score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. Despite healthy fundamentals and significant growth potential, the stock is considered fairly valued and …

Bicycle Therapeutics (BCYC) Expected to Post Earnings on Friday

Jardine Cycle & Carriage (SGX:C07) Stock Faces A Margin Gain Revenue Gap

Is Jardine Cycle & Carriage (SGX:C07) Undervalued Following Its Special Dividend And Earnings Update?

Bicycle Therapeutics Releases Q2 2026 Financial Results

Bicycle Therapeutics plc reported a narrower loss in Q2 2026 despite a significant drop in revenue. The clinical-stage pharmaceutical company posted a loss per share of $0.72, an improvement from the previous year, while revenue decreased by 78.5% to $629,000. Wall Street analysts maintain …

BlackRock (UNCY holder) reports 5.3% Unicycive Therapeutics stake in Schedule 13G

BlackRock, Inc. has filed a Schedule 13G, disclosing a passive ownership stake of 5.3% in Unicycive Therapeutics, Inc. This stake amounts to 1,413,381 shares of common stock, with BlackRock holding sole voting power over 1,391,049 shares and sole dispositive power over all 1,413,381 shares. …

BCYC Looks 71.0% Undervalued on GF Value™ Despite Revenue Drop

Bicycle Therapeutics PLC (BCYC) reported a significant Q2 revenue decline, yet its GF Value™ suggests the stock is 71.0% undervalued. The company, a clinical-stage biotech, is focused on advancing its cancer pipeline despite being unprofitable and cash-flow negative, with a moderate GF Score™ indicating …

Bicycle Therapeutics PLC 2026: Revenue $629K, EPS ($0.72) — 10-Q Summary

Bicycle Therapeutics PLC reported collaboration revenue of $629K and a net loss of ($50.33M) for the quarter ended 2026, with a diluted loss per share of ($0.72). This represents a significant decrease in revenue but an improvement in net loss compared to the prior …

Bicycle Therapeutics reports Q2 2026 results — $510.1M cash, $50.3M net loss

Bicycle Therapeutics has released its Q2 2026 results, showing $510.1 million in cash and cash equivalents and a net loss of $50.3 million. The company reported reduced R&D and G&A expenses year-over-year and projects a cash runway into 2030, citing clinical advancements in its …

Bicycle’s zelenectide shows 65% overall response rate in 26 patients

Bicycle Therapeutics reported its Q2 2026 financial results, including a net loss of $50.3 million, and provided corporate updates. Key clinical data were presented for nuzefatide pevedotin in EphA2-expressing cancers and for zelenectide pevedotin in metastatic urothelial cancer, showing promising anti-tumor activity and differentiated …

Cyclerion Therapeutics Inc (CYCN) Valuation: PE, PB & Fair Value Analysis

The article analyzes the valuation of Cyclerion Therapeutics Inc (CYCN), noting its current valuation score of 8.56, which ranks 84 out of 385 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -2.63 and mentions that relevant data for …

Cycurion Lands Largest Contract in Company History: $54.6 Million 10-Year Award with Top-5 Global Consulting Firm

Cycurion, Inc. has secured its largest contract to date, a 10-year award worth $54.6 million, in partnership with a top-5 global consulting firm. This agreement focuses on modernizing and securing a major Health and Human Services System for a state government agency, reinforcing Cycurion's …

Unicycive Therapeutics Inc Today's Market Trends | UNCY Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey

Unicycive Therapeutics Inc (UNCY) is a biotechnology company focused on kidney disease treatments, with lead drug candidate oxylanthanum carbonate (OLC) and UNI-494 in development. Despite strong fundamentals and significant institutional ownership, the stock has shown weak market performance and is currently trading sideways. Analysts, …

Bicycle Therapeutics (NASDAQ:BCYC) Given New $14.00 Price Target at Needham & Company LLC

Bicycle Therapeutics (NASDAQ: BCYC) cuts costs, ends Bayer deal as cash tops $510M

Bicycle Therapeutics earnings missed by $0.15, revenue fell short of estimates

Bicycle Therapeutics (NASDAQ: BCYC) reported second-quarter earnings per share of $-0.72, missing analyst estimates by $0.15. The company's revenue for the quarter was $630K, falling short of the consensus estimate of $4.35M. Following the announcement, Bicycle Therapeutics' stock price closed at $3.86, reflecting a …

PureCycle Technologies (PCT) to Release Earnings on Thursday

Bicycle Therapeutics PLC (BCYC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Bicycle Therapeutics PLC (BCYC), noting its current valuation score of 7.52, which ranks it 215 out of 384 in the Biotechnology & Medical Research industry. It details the company's current P/E ratio of -1.22 and indicates that …

Pure Cycle Corp (PCYO) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Pure Cycle Corp (PCYO), detailing its volatility, financial risk, and investment risk. It highlights the company's beta value of 1.26, indicating higher sensitivity to market movements compared to the S&P 500. The report also includes various metrics …

Cyclerion Therapeutics Inc (CYCN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cyclerion Therapeutics Inc (CYCN), evaluating its price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis suggests a current price momentum score of 3.73, ranking it 331 out of 384 in its …

PCYO|Pure Cycle Corp|Price:10.580|Chg%:-0.180

Pure Cycle Corporation is a diversified company operating in wholesale water and wastewater services, land development, and single-family home rentals, primarily in the Denver, Colorado area. The company's segments include water and wastewater services and land development, which encompasses master-planned communities and single-family rental …

Bicycle Therapeutics Plc Sponsored ADR Revenue Breakdown – DUS:50BA

Bicycle Therapeutics Plc Sponsored ADR (DUS:50BA) generated €61.80 million in revenue last year, primarily from its Chemically Synthesized Medicines segment. The United Kingdom was the largest contributor to this revenue. This marks an increase from the previous year's revenue of €34.07 million.

Pure Cycle: Rate Headwind, Long-Term 2027-2028 Upside (NASDAQ:PCYO)

MotorCycle Holdings (ASX: MTO) Records Revenue Growth as Acquisition Integration Shapes FY26 Outlook

Jain Resource Recycling hosts earnings call for Q1FY27 results on Aug 4

Bicycle Therapeutics plc Stock 12‑Month Price Target Cut to $10.43, Implies 165% Upside

Bicycle Therapeutics plc (BCYC) has seen its average 12-month price target cut to $10.43 from $13.62 by analysts, with a range of forecasts from $5 to $15 per share. Despite the cut, this new target implies a potential upside of approximately 165% from the …

Unicycive Therapeutics (UNCY) grants 47,941 RSUs to director Laumas

Unicycive Therapeutics director Sandeep Laumas was granted 47,941 restricted stock units (RSUs) on May 14, 2026, as reported in a Form 4/A filing. Of these, 19,976 RSUs vested upon grant, and the remaining 3,995 units will vest monthly over seven months, subject to his …

Unicycive Therapeutics (UNCY) director granted 47,941 RSUs with staged vesting

Unicycive Therapeutics director Sara Kenkare-Mitra was granted 47,941 Restricted Stock Units (RSUs) on May 14, 2026. Of these, 19,976 shares vested immediately, and the remaining 3,995 shares will vest monthly over seven months, starting June 1, 2026, contingent upon her continued service. The transaction, …

Freetech Road Recycling Technology (Holdings) Ltd. Revenue Breakdown – HKEX:6888

PureCycle Technologies and IPL Schoeller develop polypropylene tubs and lids with 25% PCR content

PureCycle Technologies and IPL Schoeller are collaborating to develop polypropylene tubs and lids that incorporate 25% post-consumer recycled (PCR) content. This initiative aims to help brands like Cleveland Kitchen comply with emerging recycled-content packaging mandates in various U.S. states. The PureFive resin used is …

Pure Cycle Corp (PCYO) Institutional Confidence

Pure Cycle Corp (PCYO) has an institutional shareholding score of 7.00, placing it 5th out of 14 in the Water & Related Utilities industry. Institutional shareholding percentage rose by 7.36% quarter-over-quarter to 76.55%. ETHSX is the largest institutional shareholder with 134.25K shares, representing 0.56% …